Back to top

Revolution Medicines Gains as Investors Continue to Digest Clinical and Regulatory Momentum

Revolution Medicines (RVMD) is up 3.1% today. Here is some analysis on what might have caused this price movement. ([ir.revmed.com](https://ir.revmed.com/news-releases/news-release-details/european-medicines-agency-expedites-assessment-revolution?utm_source=openai))

Analysis: The most likely driver is continued bullish sentiment around Revolution Medicines’ pancreatic cancer pipeline after a string of favorable updates in early July. This could be because investors are still reacting to fresh clinical data, a new European regulatory step for daraxonrasib, and higher analyst price targets issued after those developments. ([ir.revmed.com](https://ir.revmed.com/news-releases/news-release-details/european-medicines-agency-expedites-assessment-revolution?utm_source=openai))

Details:

  • The company said on July 7 that European regulators accepted daraxonrasib into a phased review process, which can support a faster path toward potential approval.
  • On July 2, Revolution Medicines presented Phase 1/2 data for zoldonrasib combination regimens in metastatic pancreatic cancer and described the results as proof-of-concept for both combinations.
  • Earlier Phase 3 data for daraxonrasib in previously treated metastatic pancreatic cancer showed a meaningful survival advantage over chemotherapy, strengthening the broader investment case for the platform.
  • Analyst sentiment also improved recently, with multiple firms lifting price targets in July after reviewing the updated cancer data, which may have helped extend momentum even without a major same-day headline.

    • Sources:

    Revolution Medicines, New England Journal of Medicine, Benzinga, Investing.com

    Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

    $RVMD Insider Trading Activity

    RVMD Insider Trades

    $RVMD insiders have traded $RVMD stock on the open market 57 times in the past 6 months. Of those trades, 0 have been purchases and 57 have been sales.

    Here’s a breakdown of recent trading of $RVMD stock by insiders over the last 6 months:

    • MARK A GOLDSMITH (See Remarks) has made 0 purchases and 16 sales selling 178,891 shares for an estimated $24,499,564.
    • MARGARET A HORN (Chief Operating Officer) has made 0 purchases and 10 sales selling 104,583 shares for an estimated $16,350,041.
    • ANTHONY MANCINI (See Remarks) has made 0 purchases and 12 sales selling 48,306 shares for an estimated $5,193,050.
    • STEPHEN MICHAEL KELSEY (See Remarks) has made 0 purchases and 2 sales selling 8,477 shares for an estimated $1,079,762.
    • SUSHIL PATEL has made 0 purchases and 9 sales selling 5,580 shares for an estimated $1,048,967.
    • JEFF CISLINI (General Counsel) has made 0 purchases and 4 sales selling 6,023 shares for an estimated $733,603.
    • JACK ANDERS (Chief Financial Officer) has made 0 purchases and 2 sales selling 5,475 shares for an estimated $698,826.
    • LIN WEI (Chief Medical Officer) sold 2,073 shares for an estimated $206,222
    • XIAOLIN WANG (See Remarks) sold 2,010 shares for an estimated $199,955

    To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

    EARLY ACCESS
    Receive RVMD Data Alerts
    Real-time alerts on filings, insider trades, and market signals — before everyone else.
    Get Alerts →

    $RVMD Hedge Fund Activity

    We have seen 317 institutional investors add shares of $RVMD stock to their portfolio, and 142 decrease their positions in their most recent quarter.

    Here are some of the largest recent moves:

    To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

    $RVMD Analyst Ratings

    Wall Street analysts have issued reports on $RVMD in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

    Here are some recent analyst ratings:

    • Guggenheim issued a "Buy" rating on 01/20/2026

    To track analyst ratings and price targets for $RVMD, check out Quiver Quantitative's $RVMD forecast page.

    $RVMD Price Targets

    Multiple analysts have issued price targets for $RVMD recently. We have seen 16 analysts offer price targets for $RVMD in the last 6 months, with a median target of $188.5.

    Here are some recent targets:

    • Michael Schmidt from Guggenheim set a target price of $235.0 on 07/09/2026
    • Joseph Catanzaro from Mizuho set a target price of $215.0 on 07/06/2026
    • Robert Burns from HC Wainwright & Co. set a target price of $195.0 on 07/06/2026
    • Robert Driscoll from Wedbush set a target price of $181.0 on 07/02/2026
    • Gregory Renza from Truist Securities set a target price of $210.0 on 06/30/2026
    • Ami Fadia from Needham set a target price of $235.0 on 06/29/2026
    • Cory Kasimov from Evercore ISI Group set a target price of $220.0 on 06/10/2026

    This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.

    Read full article here »

    In-Depth Zacks Research for the Tickers Above

    Normally $25 each - click below to receive one report FREE:

    Revolution Medicines, Inc. (RVMD)